Intensive blood pressure control resulted in a statistically but not clinically significant worsening of SF36 physical component scores vs standard control (-0.8 vs -0.2; P=0.02) in type 2 diabetes.
RCT (n=1,028)
Does intensive blood pressure control improve health-related quality of life and depression in patients with type 2 diabetes?
Intensive blood pressure targeting (SBP <120 mmHg) in type 2 diabetes does not meaningfully alter patient-reported quality of life or depression compared to standard targeting.
Tasa de eventos absoluta: -0.8% vs -0.2%
valor p: p=0.02
OBJECTIVE We tested the hypothesis that intensive (systolic blood pressure SBP 120 mmHg) rather than standard (SBP 130–139 mmHg) blood pressure (BP) control improves health-related quality of life (HRQL) in those with type 2 diabetes. RESEARCH DESIGN AND METHODS Subjects were 1,028 ACCORD (Action to Control Cardiovascular Risk in Diabetes) BP trial HRQL substudy participants who completed baseline and one or more 12-, 36-, or 48-month HRQL evaluations. Multivariable linear regression assessed impact of BP treatment assignment on change in HRQL. RESULTS Over 4.0 years of follow-up, no significant differences occurred in five of six HRQL measures. Those assigned to intensive (vs. standard) BP control had statistically significant worsening of the Medical Outcomes Study 36-item short-form health survey (SF36) physical component scores (−0.8 vs. −0.2; P = 0.02), but magnitude of change was not clinically significant. Findings persisted across all prespecified subgroups. CONCLUSIONS Intensive BP control in the ACCORD trial did not have a clinically significant impact, either positive or negative, on depression or patient-reported HRQL.
O’Connor et al. (Tue,) conducted a rct in Type 2 diabetes (n=1,028). Intensive blood pressure control vs. Standard blood pressure control (SBP 130-139 mmHg) was evaluated on Change in health-related quality of life (SF36 physical component score) (p=0.02). Intensive blood pressure control resulted in a statistically but not clinically significant worsening of SF36 physical component scores vs standard control (-0.8 vs -0.2; P=0.02) in type 2 diabetes.